These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33226181)

  • 21. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties.
    Marksteiner J; Pirchl M; Ullrich C; Oberbauer H; Blasko I; Lederer W; Hinterhuber H; Humpel C
    Pharmacology; 2008; 82(3):214-20. PubMed ID: 18810245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury.
    Grossetete M; Phelps J; Arko L; Yonas H; Rosenberg GA
    Neurosurgery; 2009 Oct; 65(4):702-8. PubMed ID: 19834375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.
    Bjerke M; Zetterberg H; Edman Å; Blennow K; Wallin A; Andreasson U
    J Alzheimers Dis; 2011; 27(3):665-76. PubMed ID: 21860087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
    Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
    J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor.
    Ferreira D; Westman E; Eyjolfsdottir H; Almqvist P; Lind G; Linderoth B; Seiger A; Blennow K; Karami A; Darreh-Shori T; Wiberg M; Simmons A; Wahlund LO; Wahlberg L; Eriksdotter M
    J Alzheimers Dis; 2015; 43(3):1059-72. PubMed ID: 25147108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
    Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
    Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome.
    Rozalem Aranha M; Iulita MF; Montal V; Pegueroles J; Bejanin A; Vaqué-Alcázar L; Grothe MJ; Carmona-Iragui M; Videla L; Benejam B; Arranz J; Padilla C; Valldeneu S; Barroeta I; Altuna M; Fernández S; Ribas L; Valle-Tamayo N; Alcolea D; González-Ortiz S; Bargalló N; Zetterberg H; Blennow K; Blesa R; Wisniewski T; Busciglio J; Cuello AC; Lleó A; Fortea J
    Alzheimers Dement; 2023 Nov; 19(11):4817-4827. PubMed ID: 37021589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
    Tarawneh R; D'Angelo G; Macy E; Xiong C; Carter D; Cairns NJ; Fagan AM; Head D; Mintun MA; Ladenson JH; Lee JM; Morris JC; Holtzman DM
    Ann Neurol; 2011 Aug; 70(2):274-85. PubMed ID: 21823155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma MMP-9/TIMP-1 ratio serves as a novel potential biomarker in Alzheimer's disease.
    Liu J; Li X; Qu J
    Neuroreport; 2023 Oct; 34(15):767-772. PubMed ID: 37695608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.
    Eyjolfsdottir H; Eriksdotter M; Linderoth B; Lind G; Juliusson B; Kusk P; Almkvist O; Andreasen N; Blennow K; Ferreira D; Westman E; Nennesmo I; Karami A; Darreh-Shori T; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger Å; Wahlberg L; Almqvist P
    Alzheimers Res Ther; 2016 Jul; 8(1):30. PubMed ID: 27389402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration.
    Capsoni S; Tiveron C; Vignone D; Amato G; Cattaneo A
    Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12299-304. PubMed ID: 20566851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels.
    Mlekusch R; Humpel C
    Neurosci Lett; 2009 Dec; 466(3):135-8. PubMed ID: 19786072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
    Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased CSF levels of nerve growth factor in patients with Alzheimer's disease.
    Hock C; Heese K; Müller-Spahn F; Huber P; Riesen W; Nitsch RM; Otten U
    Neurology; 2000 May; 54(10):2009-11. PubMed ID: 10822447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease.
    Fahnestock M; Michalski B; Xu B; Coughlin MD
    Mol Cell Neurosci; 2001 Aug; 18(2):210-20. PubMed ID: 11520181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies.
    Belrose JC; Masoudi R; Michalski B; Fahnestock M
    Neurobiol Aging; 2014 Apr; 35(4):926-33. PubMed ID: 24112788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
    Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
    J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.